Eyenovia is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies primarily for the treatment of progressive myopia, presbyopia, and improving diagnostic eye exams. We believe our breakthrough technology enables these first-in-class microdosed therapies that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.